Table 1.
Patient overview
| Group1 (8) | Group2 (8) | Group3 (8) | All (24) | |
|---|---|---|---|---|
| Sex (m:f) | 2:6 | 4:4 | 4:4 | 10:14 |
| Age at entry | ||||
| Mean (range) | 39.3 (18–68) | 35 (26–66) | 48.4 (32–83) | 43.3 (18–83) |
| ≤30 | 3 | 3 | ‐ | 6 |
| 31—50 | 3 | 2 | 6 | 11 |
| >50 | 2 | 3 | 2 | 7 |
| Duration in years | ||||
| Mean (range) | 17.3 (2–41) | 12.3 (4–25) | 26.6 (5–44) | 18.9 (2–44) |
| ≤10 | 3 | 4 | 1 | 8 |
| 11–20 | 2 | 2 | 2 | 6 |
| 21–30 | 1 | 2 | ‐ | 3 |
| >30 | 2 | ‐ | 5 | 7 |
| Syndromes | ||||
| Idiopathic generalized (9) | ||||
| JAE | 2 | ‐ | ‐ | 2 |
| JME | 1 | 2 | ‐ | 3 |
| EGTCSA | ‐ | 2 | ‐ | 2 |
| Unspecified | 2 | ‐ | ‐ | 2 |
| Focal (14) | ||||
| Temporal | 2 | 2 | 4 | 8 |
| Frontal | ‐ | 1 | 1 | 2 |
| Occipital | ‐ | 1 | ‐ | 1 |
| Multilobar | ‐ | ‐ | 2 | 2 |
| Multifocal | ‐ | ‐ | 1 | 1 |
| Migraine‐epilepsy (1) | 1 | ‐ | ‐ | 1 |
| Baseline sz frequency | ||||
| (12 months) | ||||
| 2–10 | 7 | 5 | ‐ | 12 |
| 11–50 | 1 | 3 | 6 | 10 |
| >50 | ‐ | ‐ | 2 | 2 |
| Number of sz types | ||||
| 1 | 1 | 3 | 2 | 6 |
| 2 | 4 | 3 | 3 | 10 |
| >2 | 3 | 2 | 3 | 8 |
Group 1: Intervention at seizure prodrome/aura.
Group 2: Prevention of seizures at perceived risk.
Group 3: Prevention of clusters.
JAE: Juvenile Absence Epilepsy.
JME: Juvenile Myoclonic Epilepsy.
EGTCSA: Epilepsy with generalized tonic‐clonic seizures on awakening.
The longer duration of epilepsy in group 3 is significant compared with group 2 (ANOVA, P= 0.03).